Meeting
2023 ASCO Annual Meeting
Discontinuation of immunotherapy over 2 years for patients with non–small cell lung cancer (NSCLC): A search for predictors.
Authors
Priscilla Cascetta
Institut Gustave Roussy, Villejuif, Paris, France
Priscilla Cascetta , Anna Reni , Francesco Facchinetti , May-Lucie Meyer , Mariona Riudavetz , Mihaela Aldea , Filippo Gustavo Dall'Olio , Arianna Marinello , Marco Tagliamento , Jordi Remon Masip , Benjamin Besse , David Planchard , Fabrice Barlesi , Lisa Derosa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2661)
DOI
10.1200/JCO.2023.41.16_suppl.2661
Abstract #
2661
Poster Bd #
503
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2023 ASCO Annual Meeting
Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of non-small cell lung cancer patients with brain metastases at diagnosis.
First Author: Benoît Nigen
Poster
2023 ASCO Annual Meeting
Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.
First Author: Yongzhao Li
Poster
2023 ASCO Annual Meeting
Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.
First Author: Lova Sun